Gram-negative bacillary osteomyelitis represents a real therapeutic challenge. Its management consists of a combined medical and surgical approach, including adequate surgical debridement of necrotic bone, removal of metal appliances, and prolonged parenteral administration of an antibacterial agent active against the causative organism (14) . Osteomyelitis due to Pseudomonas aeruginosa is particularly difficult to treat because of the restricted arsenal of potent antibiotics and the ease with which the organism may develop drug resistance during therapy. The current therapeutic standard is intravenous administration of a combination of an aminoglycoside and an antipseudomonal penicillin for 4 to 6 weeks (16) . Since aminoglycosides are associated with nephro-and ototoxicity and therapeutic concentrations are difficult to predict, the drug levels in the sera of patients receiving the agents should be monitored. It is not surprising, therefore, that there has been marked interest in the development of effective agents that can be given safely on an ambulatory basis.
Ciprofloxacin was effective in the treatment of P. aeruginosa infection in animal models of pneumonia and osteomyelitis (15, 20) . On the basis of these data, we elected to study the efficacy and safety of orally administered ciprofloxacin in the treatment of P. aeruginosa osteomyelitis. We used an open, noncomparative trial because of the lack of alternative oral antipseudomonal agents and because the drug was given initially on a compassionate basis after failure of standard therapy.
( Tel Aviv; E. Wolfson Hospital, Holon; Beilinson Medical Center, Petah Tikva; and HaEmek Hospital, Afula), were eligible for inclusion in the protocol. We excluded patients under 12 years of age, pregnant women, patients allergic to carboxyquinolones, and patients with advanced renal or liver impairment (serum creatinine, >2.0 mg/dl; serum glutamic pyruvic transaminase, >200 IU/liter). Initially only patients for whom standard therapy for P. aeruginosa infection failed were enrolled (six patients).
The diagnosis of osteomyelitis was made by clinical presentation, radiographic or radionucleic scan evidence, and bacteriological confirmation. Pretherapy specimens for culture were obtained by bone aspiration or biopsy at the time of orthopedic surgery. Blood specimens for culture were drawn from all febrile patients. P. aeruginosa was identified by standard methods (11) . The in vitro susceptibilities of the isolates to ciprofloxacin were determined by the KirbyBauer disk diffusion technique (2) 
DISCUSSION
Ciprofloxacin uniquely combines three advantages: excellent antipseudomonal activity, good intestinal absorption, and a paucity of side effects (10, 19) . We have successfully exploited these attributes for the oral therapy of P. aeruginosa osteomyelitis. This approach is innovative for two reasons: it offers a monotherapeutic regimen and oral drug administration for an infection for which the standard therapy includes a combination of two parenteral agents. Although several new parenteral agents, such as imipenem-cilastatin (13), ticarcillin plus clavulanate (4), and ceftazidime (1), have been used solely to treat gram-negative bacillary osteomyelitis, in most studies the number of Pseudomonas osteomyelitis cases was too small for adequate analysis. Oral drug regimens have been studied in children with osteomyelitis due mainly to gram-positive organisms (23) , and this approach has been recommended in selected cases (17) . In adult patients this experience has been anecdotal until the introduction of the new fluoroquinolones.
Ciprofloxacin therapy was remarkably effective in an animal model of chronic P. aeruginosa osteomyelitis in rabbits (15) . After a 4-week treatment, 94% of repeat culture specimens were sterile; a comparative 4-week tobramycin course resulted in 6% of the animals having sterile cultures. A 2-week regimen with ciprofloxacin was less efficacious in this model (59% of repeat bone cultures remained positive). Several investigators have studied oral administration of ciprofloxacin (usual dose, 750 mg twice a day) to patients with gram-negative bacillary osteomyelitis (3, 5-9, 12, 18, 21, 22) . Only in a few of these studies were sufficient data presented to permit evaluation of the response of P. aeruginosa osteomyelitis patients to therapy (Table 3) . Greenberg et al. (7) treated 13 patients with Pseudomonas osteomyelitis. At least one additional organism was grown in eight of the cases. The mean duration of treatment was 77 days, and the patients were monitored for a mean of 13 months. Infection recurred in five patients; in two patients, metal appliances had not been removed, and in the other three the infection was polymicrobial. Gilbert et al. (6) have treated 16 patients with chronic P. aeruginosa osteomyelitis; the treatment for six patients failed both clinically and bacteriologically, with emergence of drug resistance in four cases. In a randomized comparative trial (8) , seven cases of biopsy-or aspiration-proved P. aeruginosa osteomyelitis were treated with oral ciprofloxacin, and six patients received a standard intravenous therapy (a combination of an aminoglycoside plus an antipseudomonal ,3-lactam). In the ciprofloxacin group the mean duration of treatment was 61 days, and the mean follow-up was 5 months. The infection was cured in three cases and recurred in two cases, and treatment failed in two cases. In the standard therapy group, patients were treated for an average of 40 days and were monitored for S months; four patients were cured, one (an immunocompromised patient) relapsed, and another one improved clinically and was cured bacteriologically. Although (3) reported on seven patients with bone and joint infections due to P. aeruginosa, to whom ciprofloxacin was administered for 16 to 150 days. Two patients underwent surgical debridement; the duration of follow-up was not mentioned. Six patients were cured; the patient for whom treatment failed had an infected prosthetic hip joint which apparently was not removed, and a ciprofloxacin-resistant P. aeruginosa sp. was isolated 12 days after the initiation of therapy.
The present study of ciprofloxacin-treated P. aeruginosa ostemoyelitis is the biggest published so far and has the longest follow-up period. The 95% cure rate is markedly superior to those from previous studies. This favorable outcome could be related to several factors, including the following. (i) Longer duration of drug administration. We believe that in most forms of P. aeruginosa osteomyelitis the optimal duration of treatment should extend over 2 to 4 months. The only exception to this rule might be osteomyelitis following nail puncture of the foot, for which 1 month of therapy is probably sufficient. This approach is demonstrated by one of our patients with sternal osteomyelitis, whose treatment was inadvertently discontinued after 6 weeks of administration. Infection reappeared (the isolate remained susceptible to ciprofloxacin), and after a repeat debridement ciprofloxacin was readministered for a total of 10 weeks. The infections was cured, and the patient has remained well after 18 months of follow-up. (ii) Most of our patients had acute or subacute forms rather than chronic osteomyelitis, the latter being considered more resistant to therapy. Indeed, the only patient for whom treatment failed in our study had a chronic infection, and most failures in previous studies also occurred in chronic cases (6, 21) . It is our impression that treatment in chronic osteomyelitis should last for 4 months at least and probably extend beyond this period. (iii) Debridement, the surgical cleansing of pus and necrotic bone and removal of metal appliances, is an essential part of the therapy (24) . Seventeen of the evaluable patients in our study had adequate debridements when indicated, and all were cured. Three patients escaped the procedure, and one failed to respond to ciprofloxacin treatment. The patient underwent a thorough debridement thereafter, and following the administration of another fluoroquinolone, a lasting cure was obtained.
One of the risks of treating Pseudomonas infections with a single drug is the emergence of resistance during therapy. Although the development of ciprofloxacin resistance and the occurrence of superinfection were noted in previous studies (3, 19) , they have not been observed in the present trial despite the long periods of drug administration.
In accordance with other reports (3, 7, 10) , the safety of ciprofloxacin was remarkable. Our patients tolerated well the drug which they received for numerous weeks, and only in a single instance treatment was discontinued because of severe nausea.
Although this was a noncomparative study, our excellent results, coupled with the paucity of adverse effects, prompt us to conclude that oral ciprofloxacin treatment of acute and subacute Pseudomonas osteomyelitis represents a real therapeutic revolution. We believe that future randomized comparative trails will show that oral ciprofloxacin is at least as efficacious as standard intravenous regimens. Care should be taken in thorough debridement of necrotic bone, the removal of metal appliances, and sufficient duration of drug administration. If drug resistance does not become a common problem with widespread use of ciprofloxacin, the drug will dramatically reduce the duration of or even abolish the need for hospitalization and intravenous therapy, which are at present the rule in the treatment of osteomyelitis.
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